Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04647526 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
- 20
- Study locations
NCT04647526 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is active but no longer recruiting, run by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 455 participants, above the 191-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (138% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT04647526, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is active but no longer recruiting, sponsored by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of \[Lu-177\]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG [Lu-177]-PNT2002
Study Locations (20)
California
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- VA Greater Los Angeles Healthcare System - Los Angeles
- University of California Los Angeles, Nuclear Medicine Clinic - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- UC Irvine Chao Family Comprehensive Cancer Center - Orange
- Stanford Cancer Institute - Palo Alto
Missouri
- VA St. Louis Health Care System - St Louis
- Saint Louis University Hospital - St Louis
- Washington University School of Medicine - St Louis
Maryland
- University of Maryland Greenebaum Cancer Center - Baltimore
- Chesapeake Urology Associates (CUA) P.A. - Towson
Michigan
- University of Michigan Hospitals - Ann Arbor
- Karmanos Cancer Center - Detroit
Arizona
- Arizona Institute of Urology (AIU) - Tucson - Tucson
Colorado
- University of Colorado Hospital - Aurora
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2028-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04647526
The ClinicalTrials.gov registry entry for NCT04647526 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (138% higher). The listed sponsor is POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Enzalutamide is the first listed.
NCT04647526 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Missouri, Maryland.
Frequently Asked Questions
What is clinical trial NCT04647526 about?
NCT04647526 is a clinical study titled "Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment". The purpose of this study is to evaluate the efficacy and safety of \[Lu-177\]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).
What is the current status of trial NCT04647526?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2021-02-25. Estimated completion is 2028-03.
What conditions does trial NCT04647526 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT04647526?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), [Lu-177]-PNT2002 (DRUG).
Who is sponsoring clinical trial NCT04647526?
This trial is sponsored by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04647526 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
RECRUITING · Phase 3
-
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
RECRUITING · Phase 3
-
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.